Meena Arunachalam

Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial

Jörge E. Cortes, Samer K. Khaled, Giovanni Martinelli et al. · The Lancet Oncology · 2019 · 465 citations

Hematological Malignancy, Medicine, Hematology +5

Efficacy and Safety of Single-Agent Quizartinib (Q), a Potent and Selective FLT3 Inhibitor (FLT3i), in Patients (pts) with FLT3-Internal Tandem Duplication (FLT3-ITD)-Mutated Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) Enrolled in the Global, Phase 3, Randomized Controlled Quantum-R Trial

Jörge E. Cortes, Samer K. Khaled, Giovanni Martinelli et al. · Blood · 2018 · 36 citations

Highlights of Thirty-Year Experience of Laser Use at the Florence (Italy) Department of Dermatology

Piero Campolmi, Paolo Bonan, Giovanni Cannarozzo et al. · The Scientific World JOURNAL · 2012 · 33 citations · Full text

Soft Tissue Vaporization, Surgical Oncology, Engineering +19

Melasma: Treatment with 10% tretinoin peeling mask

Ilaria Ghersetich, Michela Troiano, Benedetta Brazzini et al. · Journal of Cosmetic Dermatology · 2010 · 31 citations

Clinical Outcomes in Patients with FLT3-ITD-Mutated Relapsed/Refractory Acute Myelogenous Leukemia Undergoing Hematopoietic Stem Cell Transplantation after Quizartinib or Salvage Chemotherapy in the QuANTUM-R Trial

Siddhartha Ganguly, Jörge E. Cortes, Alwin Krämer et al. · Transplantation and Cellular Therapy · 2020 · 29 citations · Full text